What is the appropriate approach to evaluate and manage hyponatremia, including assessment of serum sodium level, symptom severity, volume status, and treatment options?

Evaluation and Management of Hyponatremia

Hyponatremia (serum sodium <135 mmol/L) requires systematic evaluation based on volume status, symptom severity, and serum osmolality, with treatment prioritizing correction rates that prevent both neurological complications from hyponatremia itself and osmotic demyelination syndrome from overly rapid correction. 1

Initial Diagnostic Workup

Obtain serum sodium, serum osmolality, urine osmolality, urine sodium concentration, serum creatinine, and assess extracellular fluid volume status through physical examination looking specifically for orthostatic hypotension, dry mucous membranes, decreased skin turgor (hypovolemia) versus peripheral edema, ascites, jugular venous distention (hypervolemia). 1, 2

• Serum osmolality <275 mOsm/kg confirms hypotonic hyponatremia and excludes pseudohyponatremia from hyperglycemia (correct by adding 1.6 mEq/L for each 100 mg/dL glucose >100 mg/dL) 1, 3
• Urine osmolality >100 mOsm/kg indicates impaired water excretion; >300 mOsm/kg suggests SIADH or cerebral salt wasting 1
• Urine sodium <30 mmol/L predicts response to saline in hypovolemic hyponatremia (71-100% positive predictive value); >20-40 mmol/L with high urine osmolality suggests SIADH 1
• Serum uric acid <4 mg/dL has 73-100% positive predictive value for SIADH 1
• Check TSH and morning cortisol to exclude hypothyroidism and adrenal insufficiency, which must be ruled out before confirming SIADH 1

Physical examination alone has poor accuracy for volume assessment (sensitivity 41%, specificity 80%), so integrate clinical findings with laboratory parameters. 1

Symptom Severity Classification

Severe Symptomatic Hyponatremia (Medical Emergency)

• Seizures, coma, altered consciousness, confusion, delirium, respiratory distress 1, 4
• Requires immediate 3% hypertonic saline regardless of serum sodium level 1

Moderate Symptoms

• Nausea, vomiting, headache, confusion, gait instability, lethargy 4, 3

Mild/Asymptomatic

• Minimal symptoms or cognitive impairment only 4
• Even mild chronic hyponatremia (130-135 mmol/L) increases fall risk (21% vs 5%), fractures, and mortality (60-fold increase if <130 mmol/L) 1, 4, 2

Treatment Based on Symptom Severity and Volume Status

Severe Symptomatic Hyponatremia (Any Volume Status)

Administer 3% hypertonic saline 100 mL IV bolus over 10 minutes, repeatable up to 3 times at 10-minute intervals, targeting 6 mmol/L increase over first 6 hours or until symptoms resolve. 1, 3

• Check serum sodium every 2 hours during initial correction 1
• Maximum correction: 8 mmol/L in any 24-hour period to prevent osmotic demyelination syndrome 1, 3, 2
• High-risk patients (cirrhosis, alcoholism, malnutrition, prior encephalopathy): limit to 4-6 mmol/L per day, absolute maximum 8 mmol/L/24h 1
• ICU admission recommended for close monitoring 1

Hypovolemic Hyponatremia (Asymptomatic/Mild Symptoms)

Discontinue diuretics and administer isotonic saline (0.9% NaCl) for volume repletion at 15-20 mL/kg/h initially, then 4-14 mL/kg/h based on response. 1, 3

• Urine sodium <30 mmol/L confirms hypovolemic etiology 1
• Causes: GI losses, diuretics, third-spacing, burns 1
• Monitor for euvolemia: resolution of orthostatic hypotension, normal skin turgor, moist mucous membranes 1
• Still respect 8 mmol/L/24h correction limit 1

Euvolemic Hyponatremia (SIADH)

Fluid restriction to 1 L/day (or <800 mL/day for refractory cases) is first-line therapy. 1, 3, 2

• If no response after 24-48 hours, add oral sodium chloride 100 mEq three times daily 1
• Second-line options: urea (40g in 100-150 mL NS q8h), tolvaptan 15 mg daily (titrate to 30-60 mg), demeclocycline, lithium 1, 2
• Nearly half of SIADH patients fail fluid restriction alone 5
• Common causes: malignancy (especially small cell lung cancer), CNS disorders, pulmonary disease, medications (SSRIs, carbamazepine, NSAIDs, opioids, chemotherapy) 1

Hypervolemic Hyponatremia (Heart Failure, Cirrhosis)

Implement fluid restriction to 1-1.5 L/day for serum sodium <125 mmol/L. 1, 3

• Discontinue diuretics temporarily if sodium <125 mmol/L 1
• In cirrhosis: add albumin infusion (8g per liter of ascites removed) alongside fluid restriction 1
• Avoid hypertonic saline unless life-threatening symptoms present, as it worsens ascites and edema 1
• Sodium restriction (2-2.5 g/day) more effective than fluid restriction for weight loss in cirrhosis, as fluid follows sodium 1
• Consider vaptans (tolvaptan) for persistent severe hyponatremia despite fluid restriction and optimized guideline-directed therapy, but use cautiously in cirrhosis due to hepatotoxicity risk (4.4% ALT >3× ULN) and GI bleeding (10% vs 2% placebo) 1

Special Populations and Pitfalls

Neurosurgical Patients: SIADH vs Cerebral Salt Wasting (CSW)

Distinguish CSW from SIADH by volume status—CSW presents with true hypovolemia (CVP <6 cm H₂O, orthostatic hypotension, dry mucous membranes) while SIADH is euvolemic. 1

• CSW treatment: aggressive volume and sodium replacement with isotonic or hypertonic saline (50-100 mL/kg/day), NEVER fluid restriction 1
• Add fludrocortisone 0.1-0.2 mg daily for severe CSW or subarachnoid hemorrhage patients 1
• In subarachnoid hemorrhage at risk for vasospasm: never use fluid restriction, as it worsens cerebral ischemia 1
• Hydrocortisone may prevent natriuresis in SAH patients 1

Cirrhotic Patients

Hyponatremia in cirrhosis increases risk of spontaneous bacterial peritonitis (OR 3.40), hepatorenal syndrome (OR 3.45), and hepatic encephalopathy (OR 2.36). 1

• Correction rate must be especially cautious: 4-6 mmol/L per day maximum 1
• Risk of osmotic demyelination 0.5-1.5% even with careful correction 1
• Only 1.2% of cirrhotic patients with ascites have sodium ≤120 mmol/L; chronic mild hyponatremia (130-135 mmol/L) often tolerated without specific treatment 1

Overcorrection Management

If sodium rises >8 mmol/L in 24 hours, immediately discontinue current fluids, switch to D5W (5% dextrose in water), and consider desmopressin to slow/reverse the rise. 1

• Target: bring total 24-hour correction back to ≤8 mmol/L from baseline 1
• Watch for osmotic demyelination syndrome signs 2-7 days post-correction: dysarthria, dysphagia, oculomotor dysfunction, quadriparesis 1

Monitoring Protocol

• Severe symptoms: serum sodium every 2 hours during initial correction, then every 4 hours after symptom resolution 1
• Mild symptoms: serum sodium every 4-6 hours initially, then daily 1
• Asymptomatic: serum sodium every 24-48 hours 1
• Monitor electrolytes (potassium, magnesium, chloride), renal function, and volume status throughout correction 1

Critical Pitfalls to Avoid

• Never correct chronic hyponatremia faster than 8 mmol/L in 24 hours—this causes osmotic demyelination syndrome 1, 2
• Never use fluid restriction in cerebral salt wasting or SAH patients at risk for vasospasm—it worsens outcomes 1
• Never ignore mild hyponatremia (130-135 mmol/L) as clinically insignificant—it increases mortality and morbidity 1, 4
• Never delay treatment while awaiting ADH or natriuretic peptide levels—these tests are not supported by evidence and delay care 1
• Never use hypertonic saline in hypervolemic hyponatremia without life-threatening symptoms—it worsens fluid overload 1
• Inadequate monitoring during active correction risks both under- and over-correction 1
• Failing to identify and treat underlying cause (medications, malignancy, endocrine disorders) 1